Previous 10 | Next 10 |
home / stock / th:cc / th:cc news
Researchers report superior anticancer activity against cancer stem-like cells with TH1902, compared to unconjugated docetaxel First evidence for TH1902 targeting of human breast and ovarian cancer stem-like cells in vitro and in vivo Paper highlights potential mechani...
MONTREAL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Lev...
New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents. Predictive pharmacokinetic modelling shows that new methods of administration could provide similar kinetics to intravenous infusion. ...
MONTREAL, July 27, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it ...
– Q2 2022 Consolidated Sales Growth of 8.3% to $19.3 million – Year-to-Date Revenue Growth of 13.9% or $37.8 million – Year-to-Date EGRIFTA SV ® Revenue Growth of 21.5% – TH1902 Basket Trial Initiated ...
Confirmed safety profile at 300 mg/m 2 or 1.5 times the therapeutic dose of docetaxel alone Confirmed low levels of free docetaxel consistent with observations in animal studies Early signs of efficacy observed in the dose escalation portion of the study Enrollme...
Financing Will Significantly Strengthen the Balance Sheet and Extend Cash Runway Initial Draw of $40 Million Will Retire $30 Million of the Principal Amount of the Convertible Notes Due in 2023 MONTREAL, July 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“The...
MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) -- CQDM, the Quebec Breast Cancer Foundation and Theratechnologies today announced close to CAN $2 million of funding for a collaborative research project that aims to demonstrate the efficacy and safety of a potential innovative treatment for patien...
MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter...
MONTREAL, May 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Elif McDo...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
TH:CC Stock Symbol:
TSXC Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
Firan Technology Group Corporation (FTG:CA) is expected to report for Q2 2024 Theratechnologies Inc. (TH:CA) is expected to report for Q2 2024 Transat A.T. Inc. Voting and Variable Voting Shares (TRZ:CA) is expected to report $-0.66 for Q2 2024
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...